Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Search
FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US
FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Vikas joined from hospital sector
Are you considering moving into pharmaceuticals for the first time? Vikas made the leap and has never looked back.
NASH
NASH
Pets
Pets
A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Giving Back to Those Who Serve Our Country
Giving Back to Those Who Serve Our Country
Promising Phase II Results in Chronic Kidney Disease
Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Boehringer Ingelheim - Life Forward
Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal
Employees compassionately help local communities with country-wide food drive
Coming together to bring food to people in need
Importance_of_physical_activity_in_managing_COPD.pdf
Cristian Torreblanca
Cristian Torreblanca Estrada, a Corporate GFE Senior Manager Controller in Germany talks about opportunities to move between professional areas and countries
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Edda Dankmeyer
Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Where To Meet Us | Animal Health | Boehringer Ingelheim US
Click here to find out which pharmaceutical events Boehringer Ingelheim are attending over the next year and where you can get in touch with us.
Nintedanib_in_Oncology_Backgrounder.pdf
CA. Transparency in Supply Chains Act
Contact Our Team | Human Health | Boehringer Ingelheim US
Find all our contact information here as well as the latest updates on where you can meet our partnering teams virtually or in person.
Patricia Rangel | Boehringer Ingelheim Careers
"Patricia Rangel of Corporate Strategy & Consulting describes Boehringer Ingelheim as a family company that operates with the highest integrity standards."
Women Inspiring Women: 5 questions for 6 women
Women Inspiring Women: 5 questions for 6 women